This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Nuvilex Contracts With Inno Biologics, An FDA-Compliant Provider, For Initial Generation Of Cloned Cells For Future Phase 3 Clinical Trials

SILVER SPRING, Md., Sept. 17, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX) ("Company"), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today it has contracted Inno Biologics Sdn. Bhd. to generate cell clones that are the basis of the Company's future Phase 3 cancer clinical trials.

Inno Biologics, a partner of Boehringer Ingelheim (one of the world's leading pharmaceutical companies headquartered in Europe), has state-of-the-art cGMP facilities that have been constructed to comply with regulations of both US FDA and European EMEA (the European regulatory authority equivalent to the FDA). Inno Biologics is in close geographic proximity to the Fisher BioServices storage facilities in Singapore and to Austrianova Singapore.

From clones generated by Inno Biologics, those with the highest enzyme activity that activates the cancer drug ifosfamide will be advanced through further testing. Eventually the best cell clones will be propagated and one will be prepared for encapsulation as part of the Company's treatment for advanced, inoperable pancreatic cancer as well as used to develop future treatments for other cancers.

Dr. Robert F. Ryan, Nuvilex's President and CEO commented "It is important to note we have selected an FDA recognized and cGMP compliant company to carry out the critical cell cloning portion of our overall developmental plan. Nuvilex will continue to employ the most stringent and prudent criteria in selecting entities to assist us in preparing for our future clinical trials."

About Nuvilex

Nuvilex, Inc. (OTCQB:NVLX) is an international biotechnology firm focused on developing and preparing to commercialize treatments for cancer, diabetes and other diseases based on the live, therapeutically valuable, encapsulated cells platform. The Company is leveraging its cancer biology and clinical oncology research experience and expertise, particularly for use in oncology treatments, in addition to initiating the use of medical marijuana for oncology applications. For more information visit: www.nuvilex.com .

Safe Harbor Statement:

This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.

CONTACT: Investor Relations Contact:
         Marlin Molinaro
         Marmel Communications, LLC
         Ph: (702) 434-8692
         mmolinarofc@aol.com

Nuvilex logo

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,915.07 -70.54 -0.42%
S&P 500 1,964.68 -8.15 -0.41%
NASDAQ 4,396.2040 -22.83 -0.52%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs